RE: Supply Disruption - Ezetimibe with Simvastatin 10/40 mg combination tablet (Zimybe)

Due to a delay at the manufacturing site, there is a supply issue affecting Ezetimibe with Simvastatin 10/40 mg (Zimybe).

From 1 May 2026 Pharmac is funding an alternative product Ezetimibe with Simvastatin 10/40 mg (Vytorin). This is not a Medsafe approved product and should be prescribed and supplied in line with Section 29A of the Medicines Act 1981.

Further information will be added to our webpage as updates become available – Ezetimibe with simvastatin (Zimybe) 10/40 mg: Supply issue 

Please share this information:

Please share this information with your colleagues and within your networks.

If you have any questions regarding this supply issue, please contact enquiry@pharmac.govt.nz.

Ngā mihi,

Felicity | Senior Advisor Implementation

Pharmac | Te Pātaka Whaioranga

PO Box 10-254, Wellington 6140 | Level 9, 40 Mercer Street, Wellington 6011

P: 0800 660 050 | www.pharmac.govt.nz